Interleukin (IL)-4 Antibody Global Market Report 2025

The interleukin (IL)-4 antibody market size has grown strongly in recent years. It will grow from $2.13 billion in 2024 to $2.32 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing prevalence of allergic and inflammatory diseases, rising adoption of monoclonal antibody therapies, growing awareness of immunotherapy treatments, increasing healthcare expenditure, and rising focus on personalized medicine.

The interleukin (IL)-4 antibody market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising incidence of chronic respiratory disorders, increasing demand for targeted biologic therapies, expanding clinical trials for autoimmune diseases, growing investment in biosimilar development, and increasing collaborations between pharma and biotech companies. Major trends in the forecast period include advancements in antibody engineering technologies, research and development in cytokine modulation, innovations in recombinant antibody production, development of next generation biologics, and integration of artificial intelligence based drug discovery platforms.

The increasing prevalence of allergic diseases is expected to drive the growth of the interleukin (IL) 4 antibody market going forward. Allergic diseases are immune system disorders in which the body reacts excessively to harmless substances such as pollen, dust, or food, resulting in symptoms such as inflammation, itching, and difficulty in breathing. The rising prevalence of allergic diseases is attributed to urbanization and environmental changes that increase exposure to pollutants and allergens that trigger immune overreactions. Interleukin (IL) 4 antibody assists in managing allergic diseases by specifically targeting IL 4 pathways, making it effective in reducing immune system overreactions. It helps relieve symptoms such as inflammation, itching, and difficulty in breathing, improving patient comfort and quality of life. For instance, in February 2025, according to the National Asthma Council Australia (NAC), an Australia-based not-for-profit organization, Australia recorded a total of 474 asthma related deaths, reflecting a slight year on year increase of 0.2 percent from 473 deaths in 2022, with females accounting for 68.6 percent and males comprising 31.4 percent. Therefore, the increasing prevalence of allergic diseases is driving the growth of the interleukin (IL) 4 antibody market.

Major companies operating in the interleukin (IL) 4 antibody market are concentrating on developing innovative products such as next generation bispecific antibodies to address tumor resistance and enhance anti cancer effectiveness. Next generation bispecific antibodies refer to engineered antibodies designed to bind two different antigens or epitopes at the same time, enhancing therapeutic performance by modulating multiple pathways simultaneously, improving specificity, and potentially reducing adverse effects compared to traditional single target antibodies. For instance, in February 2025, Akeso Inc., a China based biopharmaceutical company, received Investigational New Drug (IND) acceptance from the China National Medical Products Administration (NMPA) for AK139, a bispecific antibody. AK139 integrates dual targeting of interleukin 4 receptor alpha and the ST2 receptor to block the interleukin 4 interleukin 13 and interleukin 33 pathways simultaneously, offering mechanistic synergy beyond single target antibodies. This approach aims to reduce inflammatory cytokine release and tissue infiltration more effectively, potentially providing stronger and more sustained control of type 2 and related inflammation in respiratory and dermatological conditions.

In June 2025, Bio T Hera Solutions Ltd., a China-based biopharmaceutical company, partnered with SteinCares S A to commercialize a proposed biosimilar of dupilumab for the treatment of chronic inflammatory diseases across Latin America for an undisclosed amount. With this partnership, Bio T Hera Solutions aims to contribute its expertise in biologics development and supply, while SteinCares will oversee the registration and commercialization processes across the region. SteinCares S A is a US based specialty healthcare company focused on IL 4 antibody therapies and research products.

Major companies operating in the interleukin (il)-4 antibody market are Sanofi S.A., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., GeneTex Inc., Miltenyi Biotec B.V. & Co. KG, GenScript Biotech Corporation, Cell Signaling Technology Inc., Elabscience Biotechnology Inc., RayBiotech Life Inc., Santa Cruz Biotechnology Inc., Atlas Antibodies AB, Creative Biolabs Inc., Abnova (Taiwan) Corporation, Wuhan Fine Biotech Co. Ltd., United States Biological LLC, NSJ Bioreagents, Boster Biological Technology Co. Ltd.

North America was the largest region in the interleukin (IL)-4 antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interleukin (IL)-4 antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the interleukin (IL)-4 antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The interleukin (IL)-4 antibody market research report is one of a series of new reports that provides interleukin (IL)-4 antibody market statistics, including interleukin (IL)-4 antibody industry global market size, regional shares, competitors with a interleukin (IL)-4 antibody market share, detailed interleukin (IL)-4 antibody market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin (IL)-4 antibody industry. This interleukin (IL)-4 antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interleukin (IL) 4 antibody is a laboratory-produced antibody that specifically targets IL 4, a cytokine that regulates the immune system, particularly by promoting Th2 cell differentiation and antibody production. It is used to detect, quantify, or neutralize IL 4 in research or therapeutic settings, assisting in the study or modulation of immune responses in conditions such as allergies, asthma, and autoimmune disorders.

The main types of interleukin (IL) 4 antibody are monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies are highly specific immunoglobulins derived from a single B cell clone that recognize a single epitope on interleukin (IL) 4 or its receptor. They are produced through hybridoma or recombinant expression systems and engineered for isotype, affinity, and effector function to ensure consistent performance in research and clinical applications. Their uses include enzyme-linked immunosorbent assay, immunohistochemistry frozen, immunohistochemistry paraffin, western blot, and others, and they are employed by end users such as pharmaceutical companies, biotechnology companies, academic and research institutions, and contract research organizations (CROs).

The interleukin (IL)-4 antibody market also includes sales of recombinant interleukin (IL)-4 neutralizing antibodies, bispecific interleukin (IL)-4 antibodies, biosimilar interleukin (IL)-4 antibodies, antibody conjugates, assay kits, and related immunoassay reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the antibodies, whether to other entities (including downstream manufacturers, wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.